US-based biotechnology firm Cavion has started patient enrolment in a Phase II clinical trial (T-CALM Study) of CX-8998 to treat essential tremor (ET).

CX-8998 is an oral calcium channel modulator being developed to selectively regulate T-type channels called Cav3 that control firing and signalling between neurons.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The T-type calcium channel modulator is intended to restore natural rhythms of the brain.

Designed to enrol 92 patients at 18 medical research centres in the country, the Phase II trial will evaluate the efficacy of CX-8998 to decrease tremors and improve quality of life.

The multi-centre, randomised, double-blind, placebo-controlled, parallel-group trial will assess subjects through standard clinical trial scales and digital markers to objectively quantify tremor.

"We believe that Cavion’s new therapy may significantly improve the quality of life of people with essential tremor, offering hope to them and their families."

Cavion chief medical officer and research and development executive vice-president Spyros Papapetropoulos said: “We believe that Cavion’s new therapy may significantly improve the quality of life of people with essential tremor, offering hope to them and their families.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The trial’s primary outcome measure is change in tremor from baseline to day 28 on the essential tremor rating assessment scale (TETRAS) Performance.

Expected to be completed next year, the trial will assess increasing doses of CX-8998 and involve videotaping of patients in order to minimise rater bias during TETRAS assessment.

The firm plans to conduct an additional sub-study with electrophysiological measures to investigate the effect of CX-8998 on neuronal networks.

The sub-study will utilise an electroencephalography (EEG) and magnetoencephalography (MEG) to record power-spectral brain activity in certain neuro-anatomical locations.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact